New diabetes management system receives FDA approval - News - Brief Article

Medical Laboratory Observer, August, 2003

In July, the FDA approved a new insulin pump and glucose (blood sugar) monitoring system to control diabetes by automatically calculating the amount of insulin needed, then sending a radio wave signal to a pump implanted in the patient's abdomen to deliver the dose. The Paradigm 512 insulin pump and Paradigm Link glucose monitor were co-developed by Medtronic MiniMed--the diabetes-management division of Medtronic--and medtech firm BD (Becton, Dickinson and Company).

By more closely mimicking the functions of a healthy human pancreas, this system represents a first step toward developing an artificial pancreas.